// App-Quantinova.ai

: Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.

Researchers

Presenter

  • Gurudatta Naik

Principal Investigators

  • Sejong Bae

  • Mollie R. De Shazo

  • Pam Dixon

  • Lynn Merritt

  • A. Oliver Sartor

  • Frederick M. Schnell

  • Guru Sonpavde

Medical Centers

  • University of Alabama at Birmingham, Birmingham, AL

  • University of Alabama, Birmingham, AL

  • Tulane University School of Medicine, New Orleans, LA

  • Central Georgia Cancer Care PC, Macon, GA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • carfilzomib Intravenous

  • Docetaxel

  • Acyclovir

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT02047253

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved